SCYX Company Profile and Key Details

SCYX has shown mixed momentum, losing -1.98% over the past week and -14.84% over the past quarter, though year-to-date performance is up 1.61%. Short-term trend indicators are mixed aligned (SMA20 -6.95%, SMA50 0.81%, SMA200 -8.1%). The stock’s 14-day RSI is 44.33 (neutral), while the ATR of 0.06 points to moderate volatility. The stock remains hovering near 52-week lows, trading -46.18% below its high and over 24.78% above its low. Average 10-day trading volume of 42.61 thousand shares is below the 3-month average of 136.15 thousand, indicating normal recent market interest.

SCYNEXIS, Inc. (NASDAQ:SCYX) closed at $4.84 USD, gaining $0.14 (2.98%) from the previous close of $4.70. The stock is currently mid-range between its 52-week high and low $3.53 and $9.52. With a market capitalization of about $30.44 million, SCYNEXIS, Inc. is classified as a micro-cap and shows market-like volatility (beta ~1.11). Key stats such as the average daily volume over the past year has been around 139.59 thousand shares, volume is running light vs its 52-week average. Headquartered in Jersey City, NJ, SCYNEXIS, Inc. operates in the Healthcare sector and the Medical - Pharmaceuticals industry. Led by CEO David Angulo, the company employs approximately 18 people and listed since May 02, 2014. SCYNEXIS, Inc. is a biotechnology company, which engages in the development of novel oral and intravenous triterpenoid antifungal for the treatment of several fungal infections, including vulvovaginal candidiasis, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections.

SCYNEXIS, Inc. generated EPS of -$0.54 over the past year. Five-year average earnings growth is 46.02%. Wall Street analysts project EPS growth of 0.25% annually over the next five years. The latest quarter delivered EPS of $0.63. The next quarter is forecast at $0.13. Next year's EPS is expected at -$73.83. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 1 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $3.00 to $3.00. The high target offers -38.02% upside. The low target suggests -38.02% downside. The mean target is $3.00. This offers -38.02% upside. SCYNEXIS, Inc. earnings surprise history is a mixed track record. The quarter that ended August 10, 2026, missed forecasts by -224.34%. The prior quarter beat by 320.0%. Over the last six quarters, Apple has recorded several small beats. These include -26.09% in May 15, 2025.

SCYNEXIS, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$0.14. This means the shares are trading below this model’s fair value.

SCYNEXIS, Inc. has 41.92 million shares outstanding. The public float is 37.57 million shares, elevated short interest at 1.70% of float. This equals 519.39 thousand shares. The short ratio is 2.71 days. Institutional investors hold 63.21% of the float. Insiders own 1.99%. PERCEPTIVE ADVISORS LLC holds 1.80 million shares, Ventech Capital II has 414.21 thousand shares and Nothias Jean-Yves has 295.08 thousand shares. Over the past six months, insider transactions show net buying. They sold 0.00 shares across 0 transactions.

SCYNEXIS, Inc. trades at a P/E ratio of -2.64, slightly below the S&P 500 average, with a price-to-sales ratio of 1.59 and a price-to-book ratio of 0.86 suggesting the stock is closer to book value. The P/FCF stands at -2.29, also below market averages.

SCYNEXIS, Inc. (NASDAQ:SCYX) shares are flat 1.61% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows SCYNEXIS, Inc. trading at a premium to the broader market with a P/E of -2.64. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $12.07, suggesting 149.38% upside. Our AI forecast model points to short-term strength (3.51% over two weeks), a medium-term rise (13.22% over three months), and a longer-term gain (8.68% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that SCYNEXIS, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 3.51%, with price expected at $5.01 by September 25, 2026, within a range of $4.62 to $5.38 3-Month Outlook: Projected rise of 13.22%, reaching $5.48 by December 10, 2026, with a range of $4.99 to $5.92. 1-Year Outlook: Projected gain of 8.68%, with price at $5.26 by September 10, 2027, within a range of $0.00 to $3.99.